Predictive Values of Blood-based RNA Signature for the FOLFIRINOX/FOLFOX Response in Advanced Pancreatic Cancer

July 18, 2023

Presently, no widely recognised or established biomarkers are specifically designed to predict the effectiveness of FOLFIRINOX/FOLFOX (chemotherapeutic treatments commonly used for various types of cancer, including colorectal and pancreatic cancer) regimens.

A blood-based RNA signature called GemciTest1 (a non-invasive test of an 11-gene blood signature score) was developed to predict the response to gemcitabine-based first-line treatment in patients with pancreatic ductal adenocarcinoma (PDAC). Gemcitabine is a chemotherapy drug commonly used in the treatment of PDAC, and having a predictive test like GemciTest could help clinicians tailor treatment decisions and improve patient outcomes.

The objective of this study2, presented at the 25th World Congress on Gastrointestinal Cancer, was to evaluate the effectiveness of a complementary blood-based RNA signature (F/FX) to predict the response to FOLFIRINOX/FOLFOX regimens in PDAC.

The F/FX shows the potential of a blood-based RNA signature as a minimally-invasive alternative to improve patient survival and implement personalised therapy in PDAC for patients treated with a FOLFIRINOX/FOLFOX regimen as first-line treatment. Notwithstanding the data are promising, additional confirmation studies are needed in a prospective trial, distinguishing patients with non-resectable locally advanced and those with metastatic tumours.


  1. Piquemal D, et al. Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma. J Gastrointest Oncol. 2023 Apr 29;14(2):997-1007. doi: 10.21037/jgo-22-946.
  2. Piquemal D, et al. Predictive values of blood-based RNA signature for the FOLFIRINOX/FOLFOX response in advanced pancreatic cancer. Annals of Oncology. June 2023;34(1):S164-S165. doi:10.1016/j.annonc.2023.04.480
Ana Martins

In order to facilitate the use of our website, we use cookies.

Please confirm if you accept our tracking cookies. When declining the cookies, you can continue visiting the website without sending data to third party services. Read our complete cookie statement here.